Publicacións en colaboración con investigadores/as de Universidade de São Paulo (2)

2023

  1. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Leukemia, Vol. 37, Núm. 3, pp. 617-626

2021

  1. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Blood, Vol. 138, Núm. 21, pp. 2031-2041